SCHEMBL23748244

SCHEMBL23748244

C=CCOc1ccccc1C(Cl)c1ccccn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.39
HPGD P15428 1/20 0.39
MAPK1 P28482 1/20 0.39
HSD17B10 Q99714 1/20 0.39
LIG1 P18858 1/20 0.38
SLC6A4 P31645 2/20 0.36
SLC22A1 O15245 1/20 0.36
LMNA P02545 1/20 0.36
CYP1A2 P05177 1/20 0.36
ADRB2 P07550 1/20 0.36
ADRB1 P08588 1/20 0.36
HTR1A P08908 1/20 0.36
CYP2D6 P10635 1/20 0.36
HTR2A P28223 1/20 0.36
ADRA1A P35348 1/20 0.36
KDM4E B2RXH2 2/20 0.36
MEN1 O00255 1/20 0.36
NPC1 O15118 1/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23748242 0.87 L3MBTL1 (0.41) TSHRHPGDMAPK1HSD17B10LIG1
SCHEMBL23748156 0.84 MAPT (0.36) TSHRHPGDMAPK1HSD17B10LIG1
SCHEMBL23748213 0.83 LIG1 (0.43) TSHRHPGDMAPK1HSD17B10LIG1
SCHEMBL24834953 0.81 L3MBTL1 (0.38) TSHRHPGDMAPK1HSD17B10LIG1
SCHEMBL23748169 0.79 TSHR (0.43) TSHRHPGDMAPK1HSD17B10LIG1
SCHEMBL6575619 0.78 HPGD (0.50) TSHRHPGDMAPK1HSD17B10LIG1
SCHEMBL24354129 0.77 POLB (0.41) TSHRHPGDMAPK1HSD17B10LIG1
SCHEMBL23748310 0.77 HTR2C (0.34) TSHRCHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL23748215 0.77 ADRA2B (0.40) TSHRHSD17B10SLC6A4HTR1ACYP2D6
SCHEMBL24834248 0.77 HPGD (0.41) TSHRHPGDMAPK1HSD17B10LIG1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS JANSSEN BIOPHARMA INC (US) 2023-01-05 US disclosed
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS JANSSEN BIOPHARMA INC (US) 2023-01-05 US disclosed
US-11312727-B1 Macrocyclic flu endonuclease inhibitors Janssen Biopharma, Inc. (US) 2022-04-26 US disclosed
US-11312727-B1 Macrocyclic flu endonuclease inhibitors Janssen Biopharma, Inc. (US) 2022-04-26 US disclosed
EP-3864020-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS Janssen BioPharma, Inc. (US) 2021-08-18 EP disclosed
CN-113195502-A Macrocyclic influenza endonuclease inhibitors 詹森生物制药有限公司 2021-07-30 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS ACE, PNP, FEN1 TSHR 2251/4885HPGD 1171/4885MAPK1 3662/4885
US-11312727-B1 Macrocyclic flu endonuclease inhibitors ACE, FEN1, PNP TSHR 2179/4885HPGD 1024/4885MAPK1 3357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.